[go: up one dir, main page]

EA201890075A1 - Инъецируемые фармацевтические композиции лефамулина - Google Patents

Инъецируемые фармацевтические композиции лефамулина

Info

Publication number
EA201890075A1
EA201890075A1 EA201890075A EA201890075A EA201890075A1 EA 201890075 A1 EA201890075 A1 EA 201890075A1 EA 201890075 A EA201890075 A EA 201890075A EA 201890075 A EA201890075 A EA 201890075A EA 201890075 A1 EA201890075 A1 EA 201890075A1
Authority
EA
Eurasian Patent Office
Prior art keywords
lefamulin
injectable pharmaceutical
pharmaceutical compositions
value
composition
Prior art date
Application number
EA201890075A
Other languages
English (en)
Other versions
EA033988B1 (ru
Inventor
Матиас Ференцик
Вернер Хайльмайер
Петер Хинсманн
Вольфганг Виха
Original Assignee
Набрива Терапьютикс Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Набрива Терапьютикс Гмбх filed Critical Набрива Терапьютикс Гмбх
Publication of EA201890075A1 publication Critical patent/EA201890075A1/ru
Publication of EA033988B1 publication Critical patent/EA033988B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение относится к инъецируемой фармацевтической композиции, содержащей соединение формулы (I)причем указанная композиция забуферирована до фармацевтически приемлемого значения pH, особенно значения pH, составляющего от 2 до 6, в частности значения pH, составляющего от 3 до 5,5, предпочтительно значения pH, составляющего около 4-5, особенно предпочтительно около 5.
EA201890075A 2015-06-17 2016-06-14 Инъецируемые фармацевтические композиции лефамулина EA033988B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562180871P 2015-06-17 2015-06-17
PCT/EP2016/063609 WO2016202788A1 (en) 2015-06-17 2016-06-14 Injectable pharmaceutical formulations of lefamulin

Publications (2)

Publication Number Publication Date
EA201890075A1 true EA201890075A1 (ru) 2018-05-31
EA033988B1 EA033988B1 (ru) 2019-12-17

Family

ID=56131530

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890075A EA033988B1 (ru) 2015-06-17 2016-06-14 Инъецируемые фармацевтические композиции лефамулина

Country Status (26)

Country Link
US (2) US12121582B2 (ru)
EP (1) EP3310331B1 (ru)
JP (1) JP6818019B2 (ru)
KR (1) KR102656841B1 (ru)
CN (1) CN107810000B (ru)
AU (1) AU2016278774C1 (ru)
BR (1) BR112017026904B1 (ru)
CA (1) CA2989372C (ru)
CY (1) CY1123722T1 (ru)
DK (1) DK3310331T3 (ru)
EA (1) EA033988B1 (ru)
ES (1) ES2843723T3 (ru)
HR (1) HRP20210010T1 (ru)
HU (1) HUE053024T2 (ru)
IL (1) IL256115A (ru)
LT (1) LT3310331T (ru)
MX (1) MX383032B (ru)
PH (1) PH12017502319A1 (ru)
PL (1) PL3310331T3 (ru)
PT (1) PT3310331T (ru)
RS (1) RS61327B1 (ru)
SI (1) SI3310331T1 (ru)
TW (1) TWI718158B (ru)
UA (1) UA121240C2 (ru)
WO (1) WO2016202788A1 (ru)
ZA (1) ZA201707998B (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4135682A1 (en) 2020-04-17 2023-02-22 Nabriva Therapeutics GMBH Therapeutic use of pleuromutilins
EP4135681B1 (en) 2020-04-17 2025-06-25 Nabriva Therapeutics GMBH Antiviral use of pleuromutilins
EP4135683A1 (en) * 2020-04-17 2023-02-22 Nabriva Therapeutics GMBH Therapeutic use of pleuromutilins
US20230183672A1 (en) * 2021-07-19 2023-06-15 JBS Science Inc. Methods for isolating circulating nucleic acids from urine samples
US20250134844A1 (en) 2022-02-09 2025-05-01 Nabriva Therapeutics GmbH Therapeutic use of pleuromutilins
EP4338732A1 (en) 2022-09-16 2024-03-20 Nabriva Therapeutics GMBH Lefamulin and its derivatives for use in the treatment of tularemia

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4130709A (en) 1977-12-08 1978-12-19 Eli Lilly And Company Pleuromutilin glycoside derivatives
BE1003647A5 (fr) * 1989-02-28 1992-05-12 Syntex Inc Composition pharmaceutique de nicardipine pour administration parenterale.
DE4023848C2 (de) 1990-07-27 1994-04-21 Huels Chemische Werke Ag Verfahren zur Herstellung von 3-C¶1¶- bis C¶6¶-Alkoxycarbonylcyclohexanpropionsäureestern
FR2772272B1 (fr) 1997-12-16 2000-01-14 Rhone Poulenc Rorer Sa Compositions pharmaceutiques a base de dalfopristine et de quinupristine et leur preparation
US6187746B1 (en) 1997-12-16 2001-02-13 Rhone-Poulenc Rorer S.A. Pharmaceutical compositions based on dalfopristine and on quinupristine, and preparation thereof
AU6382701A (en) 2000-04-04 2001-10-15 Smithkline Beecham Plc 2-hydroxy-mutilin carbamate derivatives for antibacterial use
GB0017031D0 (en) 2000-07-11 2000-08-30 Biochemie Gmbh Antimicrobials
GB0207495D0 (en) 2002-03-28 2002-05-08 Biochemie Gmbh Organic compounds
GB0209262D0 (en) 2002-04-23 2002-06-05 Biochemie Gmbh Organic compounds
GB0308114D0 (en) * 2003-04-08 2003-05-14 Glaxo Group Ltd Novel compounds
BRPI0519759A2 (pt) * 2004-12-30 2009-03-10 Astex Therapeutics Ltd composiÇÕes farmacÊuticas
JP5373393B2 (ja) 2005-06-27 2013-12-18 ナブリヴァ セラピュティクス アクチエンゲゼルシャフト ヒドロキシアミノ基またはアシルオキシアミノシクロアルキル基を含むプレウロムチリン誘導体
GB0515995D0 (en) 2005-08-03 2005-09-07 Sandoz Ag Organic compounds
EP1972618A1 (en) * 2007-03-20 2008-09-24 Nabriva Therapeutics AG Pleuromutilin derivatives for the treatment of diseases mediated by microbes
EP2159220A1 (en) * 2008-09-02 2010-03-03 Nabriva Therapeutics AG Organic compounds
US20100331812A1 (en) * 2009-06-29 2010-12-30 Nitric Biotherapeutics, Inc. Pharmaceutical Formulations for Iontophoretic Delivery of an Immunomodulator
EP2399904A1 (en) * 2010-05-26 2011-12-28 Nabriva Therapeutics AG Process for the preparation of pleuromutilins
CN103204787B (zh) * 2012-01-17 2014-10-01 北京艾百诺科技有限公司 含有取代方酸的乙酸妙林酯及其应用
CN103626693B (zh) * 2012-08-28 2016-09-14 中国科学院上海药物研究所 一类截短侧耳素衍生物、其药物组合物及其合成方法与用途
CA2912728C (en) * 2013-05-28 2021-04-13 Morphochem Aktiengesellschaft Fur Kombinatorische Chemie Combination therapy comprising oxazolidinone-quinolones for use in treating bacterial infections
TWI762573B (zh) * 2017-02-10 2022-05-01 奧地利商納畢瓦治療有限責任公司 截短側耳素之純化

Also Published As

Publication number Publication date
BR112017026904B1 (pt) 2023-10-10
HK1252534A1 (zh) 2019-05-31
KR20180030479A (ko) 2018-03-23
ES2843723T3 (es) 2021-07-20
ZA201707998B (en) 2021-04-28
CA2989372A1 (en) 2016-12-22
EP3310331B1 (en) 2020-10-14
PH12017502319A1 (en) 2018-06-25
HUE053024T2 (hu) 2021-06-28
PT3310331T (pt) 2021-01-19
CN107810000B (zh) 2021-03-12
US12121582B2 (en) 2024-10-22
RS61327B1 (sr) 2021-02-26
EA033988B1 (ru) 2019-12-17
MX2017015812A (es) 2018-07-06
WO2016202788A1 (en) 2016-12-22
TWI718158B (zh) 2021-02-11
KR102656841B1 (ko) 2024-04-12
US20250009885A1 (en) 2025-01-09
US20180360966A1 (en) 2018-12-20
UA121240C2 (uk) 2020-04-27
CY1123722T1 (el) 2022-05-27
LT3310331T (lt) 2021-01-11
EP3310331A1 (en) 2018-04-25
DK3310331T3 (da) 2021-01-11
CN107810000A (zh) 2018-03-16
AU2016278774C1 (en) 2021-11-18
CA2989372C (en) 2023-10-03
PL3310331T3 (pl) 2021-04-19
JP2018517777A (ja) 2018-07-05
HRP20210010T1 (hr) 2021-03-05
BR112017026904A2 (pt) 2018-08-14
IL256115A (en) 2018-02-28
MX383032B (es) 2025-03-13
JP6818019B2 (ja) 2021-01-20
TW201716056A (zh) 2017-05-16
AU2016278774A1 (en) 2017-12-07
AU2016278774B2 (en) 2021-07-29
SI3310331T1 (sl) 2021-02-26

Similar Documents

Publication Publication Date Title
BR112018003026A2 (pt) composições compreendendo um inibidor de pi3k e um inibidor de hdac
NZ739676A (en) Heteroaryl compounds as irak inhibitors and uses thereof
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
PH12017502051A1 (en) TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF
EA201890075A1 (ru) Инъецируемые фармацевтические композиции лефамулина
JO3780B1 (ar) مثبطات فيروبورتين جديدة
TN2016000081A1 (en) Aminoheteroaryl benzamides as kinase inhibitors
EA201690223A1 (ru) Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение
UY35300A (es) Formulación de combinación de dos compuestos antivirales
UA116395C2 (uk) ПОХІДНІ ТРИАЗОЛ[4,5-b]ПІРИМІДИНУ
UA118666C2 (uk) Похідні піразолу
PH12018501181A1 (en) Phenyl derivatives as cannabinoid receptor 2 agonists
EA201500931A1 (ru) Производные пиридин-4-ила
MX373603B (es) Activador de canales de kcnq2-5.
MX2022001796A (es) Metodos y composiciones para inhibir los sintomas asociados con la veisalgia.
MX382175B (es) Composiciones de profármaco de monometilfumarato
MX382601B (es) DERIVADOS DE QUINOXALINA Y PIRIDOPRAZINA COMO INHIBIDORES DE PI3Kß.
MX2020006434A (es) Nuevos compuestos inhibidores del blanco mecanistico de rapamicina (mtor).
BR112016024235A2 (pt) composições farmacêuticas compreendendo agentes antibacterianos
UA115583C2 (uk) Азетидинілоксифенілпіролідинові сполуки
EA201691792A1 (ru) Фармацевтические составы на основе вилдаглиптина
MX2018016339A (es) Compuestos heterociclicos antiinfecciosos y sus usos.
MX363622B (es) Nuevos derivados de amidinourea macrociclica, metodos de preparacion y usos de los mismos como inhibidores de quitinasa.
MX2020006436A (es) Compuestos inhibidores del blanco mecanistico de rapamicina (mtor).
BR112017024126B8 (pt) Composições farmacêuticas, composto a micronizado e/ou pelo menos um sal farmaceuticamente aceitável micronizado do composto a e uso dos mesmos